Following the administration of immune checkpoint inhibitors, an unexpected pattern of
response designated as hyperprogression may be observed in certain patients. This paradoxical …

Malignant pleural mesotheliomas (MPMs) often show CDKN2A and NF2 inactivation, but
other highly recurrent mutations have not been described. To identify additional driver genes, …

Malignant pleural mesothelioma (MPM) is an aggressive cancer with rising incidence and
challenging clinical management. Through a large series of whole-genome sequencing data, …

While investigating cohorts of unclassified sarcomas by RNA sequencing, we identified 19
cases with inactivation of SMARCA4, which encodes an ATPase subunit of BAF chromatin-…

Background: Transient Receptor Potential (TRP) channels are expressed in many solid
tumors. However, their expression in breast cancer remains largely unknown. Here, we …

Background Anti-programmed death-1 (PD-1) treatment for advanced non-small-cell lung
cancer (NSCLC) has improved the survival of patients. However, a substantial percentage of …

EGFR mutations are the best predictors of response to EGFR kinase inhibitors in lung
adenocarcinoma. We evaluated two mutation-specific monoclonal antibodies for the detection of …

In patients with chronic fibrosing interstitial lung disease (ILD), a progressive fibrosing
phenotype (PF-ILD) may develop, but information on the frequency and characteristics of this …

Background and Purpose— Although the ability of MRI to investigate carotid plaque
composition is well established, the mechanism and the significance of plaque gadolinium (Gd) …

SMARCA4-deficient thoracic sarcoma (SMARCA4-DTS) is a recently described entity with
an aggressive clinical course and specific genetic alterations of the BAF chromatin …